Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andre C Kalil

Showing results (271-280 of 277) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 277 results.
The New England Journal of Medicine|May 24, 2020
Remdesivir for the Treatment of Covid-19 - Final ReportJohn H Beigel, Kay M Tomashek, Lori E Dodd, et al.
Open Forum Infectious Diseases|June 29, 2023
Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test CaseAna M Ortega-Villa, Noreen A Hynes, Corri B Levine, et al.
Critical Care (London, England)|December 19, 2024
Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trialBeatriz Arns, Andre C Kalil, Guilherme G L Sorio, et al.
The Lancet. Respiratory Medicine|October 21, 2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trialAndre C Kalil, Aneesh K Mehta, Thomas F Patterson, et al.
The New England Journal of Medicine|December 11, 2020
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19Andre C Kalil, Thomas F Patterson, Aneesh K Mehta, et al.
The Lancet. Respiratory Medicine|May 26, 2022
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trialCameron R Wolfe, Kay M Tomashek, Thomas F Patterson, et al.
Nature Reviews. Microbiology|March 31, 2019
New filovirus disease classification and nomenclatureJens H Kuhn, Takuya Adachi, Neill K J Adhikari, et al.
Pageof 28

Showing results (271-280 of 277) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 277 results.
The New England Journal of Medicine|May 24, 2020
Remdesivir for the Treatment of Covid-19 - Final ReportJohn H Beigel, Kay M Tomashek, Lori E Dodd, et al.
Open Forum Infectious Diseases|June 29, 2023
Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test CaseAna M Ortega-Villa, Noreen A Hynes, Corri B Levine, et al.
Critical Care (London, England)|December 19, 2024
Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trialBeatriz Arns, Andre C Kalil, Guilherme G L Sorio, et al.
The Lancet. Respiratory Medicine|October 21, 2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trialAndre C Kalil, Aneesh K Mehta, Thomas F Patterson, et al.
The New England Journal of Medicine|December 11, 2020
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19Andre C Kalil, Thomas F Patterson, Aneesh K Mehta, et al.
The Lancet. Respiratory Medicine|May 26, 2022
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trialCameron R Wolfe, Kay M Tomashek, Thomas F Patterson, et al.
Nature Reviews. Microbiology|March 31, 2019
New filovirus disease classification and nomenclatureJens H Kuhn, Takuya Adachi, Neill K J Adhikari, et al.
Pageof 28